The Apex Times
Above the Noise
Business Wire
BusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex Times
Back to front
Moderna shares extend gains as FDA advisory panel reviews flu vaccine submission
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 18, 10:21 AM EDT

Moderna shares extend gains as FDA advisory panel reviews flu vaccine submission

Investors pushed Moderna’s stock higher on Thursday, pointing to an FDA advisory panel review of the company’s influenza vaccine application tied to its mRNA technology platform.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Moderna’s stock extended gains on Thursday as investors focused on a key regulatory milestone: an FDA advisory panel’s review of the company’s influenza vaccine application, according to a market report published by Yahoo Finance.

The article framed the move as a continuation of strong interest from the prior session, with traders weighing what the advisory process could mean for the timing and prospects of a potential FDA decision. The report did not provide dosing details, efficacy data, or an FDA target date in the material reviewed.

FDA advisory panels are typically used to support agency decision-making by gathering expert input on clinical evidence and overall risk-benefit considerations. In this case, the market attention centered on Moderna’s influenza vaccine submission built on mRNA (messenger RNA) technology, a platform that instructs cells to temporarily produce a protein associated with a target pathogen so the immune system can recognize it.

Moderna’s shares also appeared to trade as a story stock for the influenza program, with the report suggesting that near-term expectations are being driven less by broad company updates and more by the outcome of the panel’s discussion and vote.

While the report linked the rally to the advisory-panel review, it did not disclose additional specifics such as the vaccine’s name, whether the review concerned a new formulation versus an updated version, or what specific questions the panel was expected to address.

Regulatory outcomes can move biotechnology stocks quickly, but the advisory-panel step is not the final approval itself. Even after an advisory committee recommendation, the FDA still weighs the full record and determines whether and when to approve a product.

As with many late-stage regulatory milestones, the market may be sensitive to the framing of benefits and risks, the strength of clinical findings, and any manufacturing or labeling considerations. However, the market report provided in the packet did not include those elements.

Investors will likely watch what the panel indicates during the review, including any concerns raised by external experts, as well as subsequent FDA communication. Until the agency or Moderna provides more detail, it remains unclear which aspects of the submission are most consequential to the panel’s deliberations.

Why It Matters

  • Influenza vaccines are a major market, and mRNA-based submissions can become high-impact catalysts for the firms developing them.
  • FDA advisory committee scrutiny can affect near-term expectations because it shapes how investors interpret the regulatory pathway.
  • Even though advisory panel outcomes are not final approvals, the discussion can influence sentiment around likelihood and timing of authorization.
  • The market focus on a single regulatory milestone underscores how biotechnology equity performance can hinge on document-driven review cycles rather than day-to-day operations.

Sources

Key Facts

  • Moderna (NASDAQ:MRNA) shares rose on Thursday, extending a prior session’s gains.
  • The rally was attributed by a market report to attention on an FDA advisory panel reviewing Moderna’s influenza vaccine application.
  • The influenza vaccine application under review was described as tied to Moderna’s mRNA technology.
  • The report did not provide specific efficacy, safety, or dosing details in the material reviewed.
  • The report did not provide an FDA decision date or outcome from the advisory panel in the material reviewed.

Healthcare Related

Moderna shares extend gains as FDA advisory panel reviews flu vaccine submission | The Apex Times